Skip to Content

Clinical Trial Details

JAVELIN Solid Tumor

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)


Request Additional Trial Information
Full Trial Details:

Condition: Solid Tumors
Study Type: Interventional
Phase: Phase I
Study Start Date: 01/14/2013
Study Completion Date: TBD

This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts.

Active cohorts: urothelial carcinoma (efficacy) and gastric/gastroesophageal junction (GEJ) cancer (third line).

Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC), and renal cell carcinoma (RCC, first line).

NCT Number
Principal Investigator(s)
Manish Agarwal, MD
EMD Serono
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Male, Female


  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 40k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!